HH Biotechnology Holdings Co (HH Biotechnology Holdings Co) EBIT : $3.97 Mil (TTM As of Sep. 2016)

View and export this data going back to . Start your Free Trial

What is HH Biotechnology Holdings Co EBIT?

HH Biotechnology Holdings Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2016 was $1.70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2016 was $3.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HH Biotechnology Holdings Co's annualized ROC % for the quarter that ended in Sep. 2016 was 11.16%. HH Biotechnology Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 was 20.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. HH Biotechnology Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2016 was 99,325.00%.

HH Biotechnology Holdings Co EBIT Historical Data

The historical data trend for HH Biotechnology Holdings Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HH Biotechnology Holdings Co EBIT Chart

HH Biotechnology Holdings Co Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

EBIT

Get a 7-Day Free Trial

0.16

-0.23

-0.33

-2.18

3.53

HH Biotechnology Holdings Co Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
EBIT	Get a 7-Day Free Trial															0.09	1.20	0.71	0.37	1.70

Competitive Comparison of HH Biotechnology Holdings Co's EBIT

For the Real Estate Services subindustry, HH Biotechnology Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HH Biotechnology Holdings Co's EV-to-EBIT Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, HH Biotechnology Holdings Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HH Biotechnology Holdings Co's EV-to-EBIT falls into.

HH Biotechnology Holdings Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.97 Mil.

HH Biotechnology Holdings Co (OTCPK:HHBT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HH Biotechnology Holdings Co's annualized ROC % for the quarter that ended in Sep. 2016 is calculated as:

	ROC % (Q: Sep. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2016 )	+	Invested Capital (Q: Sep. 2016 ))	/ count )
=	6.524 * ( 1 - 30.24% )	/	( (41.62	+	39.935)	/ 2 )
=	4.5511424	/	40.7775
=	11.16 %

where

	Invested Capital		(Q: Jun. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.76	-	10.816	-	( 1.382	-	max(0, 13.264	-	2.588	+	1.382	))
=	41.62

	Invested Capital		(Q: Sep. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	42.751	-	11.519	-	( 3.288	-	max(0, 13.152	-	4.449	+	3.288	))
=	39.935

Note: The Operating Income data used here is four times the quarterly (Sep. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

HH Biotechnology Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2016		Q: Sep. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	6.804	/	( ( (33.319 + max(-12.721, 0))	+	(32.45 + max(-12.612, 0)) )	/	2 )
=	6.804	/	( ( 33.319	+	32.45 )	/	2 )
=	6.804	/	32.8845
=	20.69 %

where Working Capital is:

	Working Capital		(Q: Jun. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.542	+	0	+	0.0010000000000003)	-	(10.816	+	2.444	+	0.0039999999999978)
=	-12.721

	Working Capital		(Q: Sep. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.539	+	0	+	0.0010000000000003)	-	(11.519	+	1.63	+	0.0029999999999983)
=	-12.612

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HH Biotechnology Holdings Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2016 )
	=	3.973	/	0.004
	=	99,325.00 %

HH Biotechnology Holdings Co EBIT Related Terms

Thank you for viewing the detailed overview of HH Biotechnology Holdings Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

HH Biotechnology Holdings Co (HH Biotechnology Holdings Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » HH Biotechnology Holdings Co (OTCPK:HHBT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 69 Heping North Street, C-Site, 25th - 26th Floor, Presidential Building, Heping District, Shenyang, CHN, 110003

Website

http://www.greatchinaholdings.com

HH Biotechnology Holdings Co is engaged in developing, producing and marketing of healthy food, supplements, medicine, and cosmetics.

Executives

Yizhao Zhang

director

45 OLD MILLSTONE DRIVE, NIT 6, EAST WINDSOR NJ 08520

HH Biotechnology Holdings Co (HH Biotechnology Holdings Co) Headlines

No Headlines